The University of Vermont Health Network

CILcare is a biotechnology company focused on developing drug solutions for hearing and ear disorders. Utilizing advancements in auditory sciences, the company aims to enhance the early diagnosis and treatment of conditions such as synaptopathy, which is related to neurocognitive and inflammatory diseases. By providing innovative treatment options, CILcare enables healthcare professionals to offer more effective care for patients suffering from various ear-related ailments.

THEYA Healthcare is a medical device company that specializes in designing and manufacturing innovative post-surgery garments, particularly for women recovering from breast cancer surgeries. Founded by Ciara Donlon in 2015, the company emerged from a recognized need for comfortable and feminine underwear that catered to the specific requirements of women during their recovery. Theya Healthcare's flagship product line features bras made from a unique bamboo blend fabric, which is proven to be antibacterial, highly absorbent, and effective at wicking moisture away from the skin. Clinical trials conducted in Dublin demonstrated that patients wearing Theya Healthcare bras experienced significant improvements in body image and health status, while also reporting reduced pain and discomfort compared to competing products. Since its inception, Theya Healthcare has garnered numerous accolades for its contributions to women's health, including the Cartier Women's Initiative Award and recognition in the EY Entrepreneur of the Year program.

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

BioFactura, Inc. is a biotechnology company based in Frederick, Maryland, focused on developing and manufacturing high-value biosimilars, biodefense medical countermeasures, and client-selected novel drugs. The company utilizes its patented StableFast Biomanufacturing Platform, which enables the rapid generation of stable NS0 cell lines for biopharmaceutical manufacturing. This platform features a chemically-defined, serum- and cholesterol-free production medium, pre-adapted parental cells, and modular expression vectors, allowing for the development of clonal production cell lines that can yield over one gram of product in less than eight weeks. Additionally, BioFactura offers a range of services, including expression system development, purification process development, microbial and cell culture process development, custom analytical development, and scale-up manufacturing services. The company also provides research, consulting, and contract services, thereby supporting the commercialization of innovative medical products with enhanced speed and quality. Established in 2001, BioFactura aims to meet the growing demands in the biopharmaceutical sector.